{
    "clinical_study": {
        "@rank": "11656", 
        "arm_group": [
            {
                "arm_group_label": "Empagliflozin", 
                "arm_group_type": "Experimental", 
                "description": "Empagliflozin once daily"
            }, 
            {
                "arm_group_label": "Sitagliptin", 
                "arm_group_type": "Active Comparator", 
                "description": "Sitagliptin once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess safety and efficacy of empagliflozin compared to\n      sitagliptin in patients with type 2 diabetes mellitus who are treatment-naive or on\n      treatment with metformin and have insufficient glycaemic control. The study will assess\n      non-inferiority of empagliflozin to sitagliptin with regards to HbA1c."
        }, 
        "brief_title": "Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Inclusion criteria:\n\n          -  Diagnosis of type 2 diabetes mellitus.\n\n          -  Male and female patients on diet and exercise regimen who are:\n\n          -  Treatment-na\u00efve, defined as absence of any oral antidiabetic therapy for 12 weeks\n             prior to randomisation.\n\n        or\n\n          -  Pre-treated with immediate release metformin unchanged for 10 weeks prior to\n             randomisation. Minimum dose for metformin: >=1500 mg/day or maximum tolerated dose or\n             maximum dose according to local label.\n\n          -  HbA1c of >= 7.5 % and <= 10.5 % at Visit 1 and 3.\n\n          -  Age >= 18 yrs.\n\n        Exclusion criteria:\n\n          -  Uncontrolled hyperglycaemia with a glucose level >270 mg/dL (>15 mmol/L) after an\n             overnight fast during dose stabilisation (if applicable) and/or placebo run-in.\n\n          -  Any other antidiabetic drug within 12 weeks prior to randomisation (applicable to\n             treatment-na\u00efve patients).\n\n          -  Any other antidiabetic drug within 10 weeks prior to randomisation except metformin\n             (applicable to patients on background treatment with metformin).\n\n          -  Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or\n             TIA within 3 months prior to informed consent.\n\n          -  Indication of liver disease.\n\n          -  Moderate to severe renal impairment.\n\n          -  Bariatric surgery within the past two years.\n\n          -  Treatment with anti-obesity drugs 3 months prior to informed consent.\n\n          -  Current treatment with systemic steroids at time of informed consent or any other\n             uncontrolled endocrine disorder except type 2 diabetes mellitus."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "834", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984606", 
            "org_study_id": "1245.22", 
            "secondary_id": "2013-000060-29"
        }, 
        "intervention": [
            {
                "arm_group_label": "Empagliflozin", 
                "description": "Empagliflozin once daily", 
                "intervention_name": "Empagliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Empagliflozin", 
                "description": "Placebo matching empagliflozin", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sitagliptin", 
                "description": "Sitagliptin once daily", 
                "intervention_name": "Sitagliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sitagliptin", 
                "description": "Placebo matching sitagliptin", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sitagliptin"
        }, 
        "lastchanged_date": "February 5, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase IIIb Randomised, Double-blind, Active-controlled, Parallel Group, Efficacy and Safety Study of Once Daily Oral Administration of Empagliflozin 25 mg Compared to Sitagliptin 100 mg During 52 Weeks in Type 2 Diabetes Mellitus Patients Who Are Treatment-na\u00efve or on Treatment With Metformin With Insufficient Glycaemic Control", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Colombia:", 
                "Hungary: National Institute of Pharmacy", 
                "Mexico:", 
                "Romania: National Medicines Agency", 
                "Russia: Pharmacological Committee, Ministry of Health", 
                "Spain: Ministry of Health", 
                "Sweden: Medical Products Agency", 
                "United Arab Emirates: General Authority for Health Services for Abu Dhabi", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The change from baseline in HbA1c after 52 weeks of treatment.", 
            "safety_issue": "No", 
            "time_frame": "Baseline and week 52"
        }, 
        "removed_countries": {
            "country": "Canada"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984606"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The change in bodyweight (kg) from baseline after 52 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline and week 52"
            }, 
            {
                "measure": "The change in Systolic Blood Pressure (SBP) from baseline after 52 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline and week 52"
            }, 
            {
                "measure": "The coefficient of durability of HbA1c response between 24 weeks and 52 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "Week 24 and week 52"
            }, 
            {
                "measure": "The change in Diastolic Blood Pressure (DBP) from baseline after 52 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline and week 52"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "collaborator": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}